ASX/Media Releases 2010-2012

2011

Clinical study confirms Benitec’s gene-silencing technology is safe and effective in Gradalis’ cancer vaccine	January 10, 2012
Pfizer and Tacrere Publish Pre-Clinical Results With Benitec’s ddRNAi	January 9, 2012
Bioshares Investor Report: Benitec – Building Proof of Concept Data in Four Diseases	November 25, 2011
Van Leeuwenhoeck Institute Report	November 28, 2011
Biotech Daily Release	November 20, 2011
Chief Investigators Group - Investor Presentation	November 18, 2011
Therapeutic Program Update	November 17, 2011
Chairman's Address AGM	November 17, 2011
Results of Annual General Meeting	November 17, 2011
Benitec Announces a New Therapeutic Program	October 31, 2011
Lead pain program to also target morphine intolerance	October 28, 2011
Appendix 4C - Quarterly	October 25, 2011
Patents Granted in US and Europe	October 24, 2011
Annual General Meeting Proxy Form	October 18, 2011
Notice of Annual General Meeting	October 18, 2011
Annual Report to Shareholders	October 18, 2011
Hepatitis program patents	October 6, 2011
European BioPartnering presentations	September 27, 2011
Pain Programme Update	September 19, 2011
Benitec's Appendix 4E and Full Year 2011 Statutory Accounts	Aug 24, 2011
Benitec Investor Newsletter	Aug 10, 2011
Change of Directors Interest Notice x4	Aug 10, 2011
Benitec Patent Estate Strengthened Further with Another Gene Silencing Graham Family Patent Allowed in the US	Aug 8, 2011
Benitec moves Operations to Sydney, replaces Chief Financial Officer	Aug 5, 2011
New Office Address and Contact Details	Jul 29, 2011
Appendix 4C Quarterly Cash Flow Update	Jul 29, 2011
Another Patent in Graham Family Allowed in US	Jul 27, 2011
Appendix 3B	Jun 30, 2011
Benitec's Pain Program Validated by Independent Study	Jun 20, 2011
Appendix 3B Partial Conversion	Jun 3, 2011
Notice of Initial Substantial Holder	Jun 1, 2011
Benitec's Gene Silencing Technology Used by Johns Hopkins' Scientists in the Development of a Treatment for Radio-Resistant Prostate Cancer	May 31, 2011
Appointment of Joint Company Secretary	May 26, 2011
Benitec granted another RNA Interference Patent in Japan: Further Expansion of the patent estate for the Hepatitis C Program	May 25, 2011
Benitec CEO's presentation to BioEquity Europe 2011	May 24, 2011
Top 20 Holders BLTOB Listed Options	May 20, 2011
Appendix 3B Correction	May 20, 2011
Renounceable Rights Issue - Share Allotment	May 19, 2011
Appendix 3B Renounceable Rights Issue	May 19, 2011
Benitec raises AU$8 million to Forge Ahead with its Gene Silencing Therapeutics: Rights Issue Closes Oversubscribed	May 17, 2001
Results of General Meeting	May 12, 2011
More patents granted in Europe and the US Significantly Strengthen Benitec’s Dominant Global Intellectual Property Position in Gene Silencing	May 4, 2011
Benitec Chosen to Present at BioEquity Europe 2011, May 23, Paris, France	May 4, 2011
Appendix 4C Quarterly Cash Flow Update	Apr 29, 2011
Despatch of Renounceable Rights Issue Documents	Apr 28, 2011
Appendix 3B Partial Conversion	Apr 18, 2011
Notice of General Meeting/Proxy Form	Apr 13, 2011
Letter to Overseas Shareholders	Apr 13, 2011
Letter to Australian & NZ Shareholders	Apr 13, 2011
Letter to Option Holders	Apr 13, 2011
Boardroom Radio Interview	Apr 12, 2011
Appendix 3B Rights Issue	Apr 11, 2011
Renounceable Rights Issue - Prospectus	Apr 11, 2011
Capital Raising and Changes to Capital Funding Arrangements	Apr 11, 2011
Change of Director's Interest Notice x2	Apr 7, 2011
Trading Halt	Apr 7, 2011
Options Update and Appendix 3B	Apr 4, 2011
Benitec Technology used by University of Queensland Scientists to Develop a Treatment for Cervical Cancer	Mar 29, 2011
Research Report on Benitec Released	Mar 24, 2011
RNAi Patent Update	Mar 22, 2011
Second US Clinical Study Using Benitec's ddRNAi Technology Announced	Mar 21, 2011
Becoming a Substantial Holder	Mar 11, 2011
Option Expiry Notice	Mar 3, 2011
Half Year Report and Appendix 4D	Feb 25, 2011
Hepatitis B RNAi Program Moves to the Next Stage	Feb 22, 2011
Formation of Chief Investigators Group	Feb 18, 2011
Patent Update: Strengthening and Expansion of Benitec's Dominant Patent Position in RNAi	Feb 17, 2011
Appendix 4C Quarterly Cash Flow Update	Jan 31, 2011
Appendix 3B and Cleansing Notice	Jan 24, 2011
Response to ASX Price Query	Jan 20, 2011
Appendix 3B CSIRO Top Up Shares	Jan 11, 2011
Release of Securities from Voluntary Escrow	Jan 10, 2011
Appendix 3B and Cleansing Notice	Jan 7, 2011

2010

Benitec receives Dividend from Licensee	Dec 23, 2010
Review of Pending US Divisional Patent Applications	Dec 16, 2010
Share Trading Policy	Dec 14, 2010
Correction to Appendix 3B	Dec 13, 2010
Benitec Granted Another RNA Interference Patent in Europe	Dec 13, 2010
Appendix 3B Exercise of Options	Dec 6, 2010
Appendix 3B Partial Conversion	Dec 1, 2010
Results of Meeting	Nov 26, 2010
Chairman's Address to AGM	Nov 26, 2010
Benitec Key Patent - Notice of Intent to Re-Issue in the USA	Nov 8, 2010
Benitec UK Patent Update	Nov 5, 2010
Cleansing Notice	Nov 4, 2010
Benitec Cash Flow Update	Oct 29, 2010
Appendix 4C Quarterly Cash Flow Report	Oct 28, 2010
Appendix 3B Partial Conversion	Oct 27, 2010
Annual Report 2010	Oct 27, 2010
Notice of Annual General Meeting/Proxy Form	Oct 27, 2010
Ceasing to be a Substantial Holder	Oct 22, 2010
Appendix 3B Partial Conversion	Oct 1, 2010
Benitec Launches New Pain Therapeutic Program	Oct 1, 2010
Further Update - Successful USPTO Board of Appeals Decision	Sep 30, 2010
USPTO Board of Appeals reverses all '099 Graham Patent Rejections	Sep 30, 2010
Appendix 3B Partial Conversion	Sep 29, 2010
Successful Grant of Further Hepatitis C RNAi Patent in US	Sep 29, 2010
Full Year Statutory Accounts	Sep 24, 2010
Appendix 3B Partial Conversion	Sep 20, 2010
Appendix 3B Partial Conversion	Sep 15, 2010
R&D Pipeline and Strategy Update	Sep 3, 2010
Another Patent in Graham Family Granted in US	Sep 2, 2010
Preliminary Final Report	Aug 31, 2010
Cleansing Notice	Aug 20, 2010
Appendix 3B Partial Conversion	Aug 17, 2010
Response to ASX Query re Appendix 4C	Aug 11, 2010
099 Graham Patent Re-examination Hearing at USPTO	Aug 5, 2010
Company Contact Details	Jul 29, 2010
Appendix 3B CSIRO Top Up Shares	Jul 29, 2010
Appendix 3B Partial Conversion	Jul 28, 2010
Appendix 4C Quarterly Cash Flow Report	Jul 28, 2010
Benitec Continues to Expand Patent Portfolio in Gene Expression	Jul 14, 2010
Benitec Securities Update and Appendix 3B	Jul 14, 2010
Release of Securities from Voluntary Escrow	Jul 8, 2010
Results of Meeting	Jun 30, 2010
Benitec granted Hepatitis C RNA Interference Patent in US	Jun 18, 2010
Benitec HIV/AIDS Stem Cell Clinical Trial results published	Jun 17, 2010
Initial Results from Lung Cancer Collaboration published	Jun 16, 2010
CEO Principal Terms and Conditions of Employment	Jun 15, 2010
Benitec appoints Dr Peter French as CEO	Jun 15, 2010
Appendix 3B Conversion of Portion of Note	Jun 11, 2010
Initial Director's Interest Notice	Jun 2, 2010
Benitec US Patent Re-exam Update	Jun 2, 2010
Benitec appoints Mr Iain Ross as Director	Jun 1, 2010
Notice of General Meeting/Proxy Form	May 31, 2010
Appendix 4C Quarterly Cash Flow Report	Apr 29, 2010
Benitec raises USD$6.0 Million via Convertible Note	Apr 12, 2010
Final Director's Interest Notice	Mar 31, 2010
Benitec Board and Senior Management Update	Mar 29, 2010
Benitec Graham Patent Granted in Japan	Mar 12, 2010
Benitec US Patent Re-exam Update	Mar 9, 2010
Change in Substantial Holding	Mar 5, 2010
Company Contact Details	Feb 26, 2010
Half Yearly Report and Accounts	Feb 25, 2010
Appendix 3B Issue of Shares	Feb 25, 2010
Benitec Licensee achieves Significant Milestone with Pfizer	Feb 5, 2010
Initial Director's Interest Notice	Feb 3, 2010
Benitec appoints Dr John Chiplin as Director	Feb 1, 2010
Appendix 4C Quarterly Cash Flow Report	Jan 29, 2010
US Graham Patent 10/646,070 Notice of Allowance	Jan 29, 2010
Benitec US Re-exam Update	Jan 13, 2010
Appendix 3B Issue of Shares	Jan 11, 2010
Company Contact Details	Jan 11, 2010
Trading Halt	Jan 11, 2010
Benitec and CSIRO reach Win-Win Agreement	Jan 4, 2010